Biologics & Biosimilars
Biologics are medicines made from living cells through highly complex manufacturing processes and must be handled and administered under carefully monitored conditions. Biologics are used to prevent, treat, diagnose, or cure a variety of diseases including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases. A biosimilar is exactly what its name implies — it is a biologic that is “similar” to another biologic drug already approved by the FDA. Under U.S. law, a biosimilar is approved based on a showing that it is “highly similar” to an FDA-approved biological product, known as a reference product. It may not have any clinically meaningful differences in terms of safety and effectiveness from the reference product.
- Bio-analytics for biosimilars
- Extrapolation and Interchangeability
- Legal considerations for biosimilars
- Biosimilar uptake and market considerations
- Challenges and regulatory approach for biosimilars
- Future of next generation biosimilars
Related Conference of Biologics & Biosimilars
Biologics & Biosimilars Conference Speakers
Recommended Sessions
- Bio-Pharmaceutics
- Biologics & Biosimilars
- Clinical and Hospital Pharmacy
- Clinical Trials and Clinical Research
- Drug Targeting and Design
- Industrial and Physical Pharmacy
- Nanomedicine and Biomedical Applications
- Novel Drug Delivery Systems
- Pharmaceutical Analysis
- Pharmaceutical Biotechnology
- Pharmaceutical Chemistry
- Pharmaceutical Formulation
- Pharmaceutical Manufacturing
- Pharmaceutical Microbiology
- Pharmaceutical Nanotechnology
- Pharmaceutical Packaging
- Pharmaceutical Process Validation
- Pharmacogenetics and Genomics
- Pharmacognosy and Phytochemistry
- Pharmacological Sciences
- Pharmacovigilance and Drug Safety
- Pharmacy Education and Practice
- Regulatory Affairs and Intellectual Property Rights